Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel

Journal of Neural Transmission

Volumn 118, Issue 9, 2011, Pages 1329-1333

  Müller, Thomas ^a,b   Jugel, Constanze ^c   Ehret, Reinhard ^d   Ebersbach, Georg ^e   Bengel, Gunar ^f   Muhlack, Siegfried ^b   Klostermann, Fabian ^c  

^a St Joseph Hospital   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d Beelitz Heilstätten ^*  (Germany)

^e Movement Disorders Clinic   (Germany)

^f Ernst von Bergmann Hospital   (Germany)

Author keywords

Duodenal levodopa carbidopa infusion; Homocysteine; Parkinson's disease

Indexed keywords

3 O METHYLDOPA; CARBIDOPA PLUS LEVODOPA; HOMOCYSTEINE; LEVODOPA;

AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; FEMALE; HUMAN; MALE; PARKINSON DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL;

EID: 80052460726     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0614-9     Document Type: Article

References (25)

1. A Antonini G Bondiolotti F Natuzzi SR Bareggi 2010 Levodopa and 3-OMD levels in Parkinson patients treated with duodopa Eur Neuropsychopharmacol 20 683 687 20570113 10.1016/j.euroneuro.2010.04.010 1:CAS:528:DC%2BC3cXhtV2iurbN
2. P Benetello M Furlanut M Fortunato F Pea M Baraldo 1997 Levodopa and 3-O-methyldopa in cerebrospinal fluid after levodopa-carbidopa association Pharmacol Res 35 313 315 9264047 10.1006/phrs.1997.0145 1:CAS:528: DyaK2sXls1yhsbY%3D (Pubitemid 27331190)
3. G Chandra PK Gangopadhyay KS Senthil Kumar KP Mohanakumar 2006 Acute intranigral homocysteine administration produces stereotypic behavioral changes and striatal dopamine depletion in Sprague-Dawley rats Brain Res 1075 81 92 16487496 10.1016/j.brainres.2005.12.073 1:CAS:528:DC%2BD28XisF2ltL8%3D
4. Y Furukawa N Tomioka W Sato E Satoyoshi K Hayashi S Furukawa 1989 Catecholamines increase nerve growth factor mRNA content in both mouse astroglial cells and fibroblast cells FEBS Lett 247 463 467 2714445 10.1016/0014-5793(89)81391-2 1:CAS:528:DyaL1MXktVWgtLc%3D (Pubitemid 19129298)
5. GL Hortin N Seam GT Hoehn 2006 Bound homocysteine, cysteine, and cysteinylglycine distribution between albumin and globulins Clin Chem 52 2258 2264 17068168 10.1373/clinchem.2006.074302 1:CAS:528:DC%2BD2sXhvQ%3D%3D (Pubitemid 44925000)
6. K Imamura T Takeshima K Nakaso K Nakashima 2007 Homocysteine is toxic for dopaminergic neurons in primary mesencephalic culture Neuroreport 18 1319 1322 17762705 10.1097/WNR.0b013e3282aaa0b4 1:CAS:528:DC%2BD2sXpvVajtrs%3D (Pubitemid 47344314)
7. ES Lee H Chen KF Soliman CG Charlton 2005 Effects of homocysteine on the dopaminergic system and behavior in rodents Neurotoxicology 26 361 371 15935208 10.1016/j.neuro.2005.01.008 1:CAS:528:DC%2BD2MXltFensrg%3D (Pubitemid 40780013)
8. D Manca G Cossu D Murgia A Molari P Ferrigno E Marcia M Melis 2009 Reversible encephalopathy and axonal neuropathy in Parkinson's disease during duodopa therapy Mov Disord 24 2293 2294 19795477 10.1002/mds.22807
9. B Meiler J Andrich T Müller 2008 Rapid switch from oral antiparkinsonian combination drug therapy to duodenal levodopa infusion Mov Disord 23 145 146 17987653 10.1002/mds.21800 (Pubitemid 351281236)
10. T Müller 2008 Role of homocysteine in the treatment of Parkinson's disease Expert Rev Neurother 8 957 967 18505360 10.1586/14737175.8.6.957 (Pubitemid 351872599)
11. T Müller 2010 Catechol-O-methyltransferase enzyme: cofactor S-adenosyl-l-methionine and related mechanisms Int Rev Neurobiol 95 49 71 21095459 10.1016/B978-0-12-381326-8.00004-1
12. T Müller W Kuhn 2006 Tolcapone decreases plasma levels of S-adenosyl-l-homocysteine and homocysteine in treated Parkinson's disease patients Eur J Clin Pharmacol 62 447 450 16758261 10.1007/s00228-006-0132-0 (Pubitemid 43873716)
13. T Müller W Kuhn 2009 Homocysteine levels after acute levodopa intake in patients with Parkinson's disease Mov Disord 24 1339 1343 19425084 10.1002/mds.22607
14. T Müller S Muhlack 2010 Acute homocysteine rise after repeated levodopa application in patients with Parkinson's disease Parkinsonism Relat Disord 16 688 689 20719554 10.1016/j.parkreldis.2010.07.012
15. T Müller K Renger W Kuhn 2004 Levodopa-associated increase of homocysteine levels and sural axonal neurodegeneration Arch Neurol 61 657 660 15148140 10.1001/archneur.61.5.657 (Pubitemid 38637680)
16. T Müller UE Lang S Muhlack J Welnic R Hellweg 2005 Impact of levodopa on reduced nerve growth factor levels in patients with Parkinson disease Clin Neuropharmacol 28 238 240 16239764 10.1097/01.wnf.0000183447.58529. 79 (Pubitemid 41579622)
17. T Müller C Erdmann S Muhlack D Bremen H Przuntek O Goetze D Woitalla 2006 Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease J Neural Transm 113 1441 1448 16604302 10.1007/s00702-006-0442-5 (Pubitemid 44435882)
18. D Nyholm AI Nilsson Remahl N Dizdar R Constantinescu B Holmberg R Jansson SM Aquilonius H Askmark 2005 Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease Neurology 64 216 223 15668416 10.1212/01.WNL.0000149637.70961.4C 1:STN:280:DC%2BD2M%2FktFSnsQ%3D%3D
19. PE O'Suilleabhain V Sung C Hernandez L Lacritz RB Dewey Jr T Bottiglieri R az-Arrastia 2004 Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations Arch Neurol 61 865 868 15210523 10.1001/archneur.61.6.865 (Pubitemid 38747325)
20. Onofrj M, Bonanni L, Cossu G, Manca D, Stocchi F, Thomas A (2009) Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during l-dopa gel treatment. Parkinsonism Relat Disord 15(Suppl 3): S233-S236
21. JD Rogers A Sanchez-Saffon AB Frol R az-Arrastia 2003 Elevated plasma homocysteine levels in patients treated with levodopa: association with vascular disease Arch Neurol 60 59 64 12533089 10.1001/archneur.60.1.59 (Pubitemid 36078109)
22. C Toth MS Brown S Furtado O Suchowersky D Zochodne 2008 Neuropathy as a potential complication of levodopa use in Parkinson's disease Mov Disord 23 1850 1859 18785232 10.1002/mds.22137
23. C Toth K Breithaupt S Ge Y Duan JM Terris A Thiessen S Wiebe DW Zochodne O Suchowersky 2010 Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease Ann Neurol 68 28 36 20582991 10.1002/ana.22021 1:CAS:528:DC%2BC3cXpslagsrY%3D
24. C Toth O Suchowersky D Zochodne 2010 Reply: neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view Mov Disord 25 525 20155864 10.1002/mds.22879
25. WQ Zhao Z Williams KR Shepherd JS Reuben ES Lee S rling-Reed N Lamango KF Soliman CG Charlton 2002 S-adenosyl-methionine-induced apoptosis in PC12 cells J Neurosci Res 69 519 529 12210845 10.1002/jnr.10314 1:CAS:528: DC%2BD38XmtVOgsr0%3D (Pubitemid 34831412)